



Clinical Specialty Infusions, LLC

Phone: 833-569-1005 | Fax: 430-200-4889 | Online: deliver.myforcura.com

IMMUNE GLOBULIN ENROLLMENT FORM – AUTOIMMUNE

Account manager: _____

Contact info: _____

✂ AZ: Please detach before submitting to a pharmacy.

PATIENT INFORMATION

Patient Name:		Patient/Caregiver (if applicable):	
Address:		City:	State: Zip:
Main phone:	Alternate phone:	Email:	Last 4 of SSN (required):
Date of birth:	<input type="checkbox"/> Male or <input type="checkbox"/> Female	Height (required): <input type="checkbox"/> cm or <input type="checkbox"/> inches	Weight (required): <input type="checkbox"/> lb or <input type="checkbox"/> kg
Is this the FIRST dose of Ig? <input type="checkbox"/> Yes or <input type="checkbox"/> No		Prior Ig product(s) used:	
Allergies:		Current medications:	

Please include face sheet, H&P, clinicals, and any available lab results.

CLINICAL INFORMATION – PRIMARY DIAGNOSIS ICD-10

<input type="checkbox"/> G25.82 - Siff-person syndrome	<input type="checkbox"/> G70.00 - Myasthenia Gravis without (acute) exacerbation
<input type="checkbox"/> G35 - Multiple sclerosis (MS)	<input type="checkbox"/> G70.01 - Myasthenia Gravis with (acute) exacerbation
<input type="checkbox"/> G61.0 - Acute infective polyneuritis (Guillain-Barré syndrome)	<input type="checkbox"/> L10.0 - Pemphigus (pemphigus foliaceus, pemphigus vulgaris)
<input type="checkbox"/> G61.81 - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	<input type="checkbox"/> L12.0 - Pemphigoid
<input type="checkbox"/> G61.82 - Multifocal motor neuropathy (MMN)	<input type="checkbox"/> M33.10 - Dermatomyositis
<input type="checkbox"/> G61.89 - Inflammatory polyneuropathy, unspecified	<input type="checkbox"/> M33.20 - Polymyositis
	<input type="checkbox"/> Other: _____

PRESCRIPTION AND ORDERS

Specific IG product, if desired (Pharmacist will choose appropriate product for patient if left blank):

Route: <input type="checkbox"/> Intravenous <input type="checkbox"/> Subcutaneous Access: <input type="checkbox"/> Peripheral <input type="checkbox"/> PICC <input type="checkbox"/> Port <input type="checkbox"/> Other: _____	IV Dosing (standard neuro): <input type="checkbox"/> Initial = IG 10% 2 gm/kg IV over 5 days <input type="checkbox"/> Ongoing = IG 10% 1 g/kg IV Q every 4 weeks IV Dosing (other): <input type="checkbox"/> Initial = _____ g/kg IV over _____ days <input type="checkbox"/> Ongoing = _____ g/kg IV over _____ days every _____ weeks	Dispense: <input type="checkbox"/> 1 month Rate: Start at 20mL/hr and titrate up based on the individual product to a max of 0.08 mL/kg/min. Rates will be individualized for each patient based on tolerability. Refills: 1 year or x _____ Supplies: Dispense ancillary supplies, including ambulatory infusion pump, as needed to provide home infusion therapy.
--	--	--

Orders:

Clinical Pharmacist to dose and send orders for review/signature.

Labs: CBC and CMP with each infusion, OR _____

Pre-Treatment: Dispense quantity sufficient <ul style="list-style-type: none"> Acetaminophen 500mg tab: 1-2 tablets by mouth 15-30 min prior to infusion Diphenhydramine 25mg tab: 1-2 tablets by mouth 15-30 min prior to infusion Hydration: NS 0.9% 100-500 mL IV over 30 min before each infusion, as needed 	Adverse/Anaphylactic Reactions, per protocol: <ul style="list-style-type: none"> Epinephrine 1:1000, 1 mL ampule OR EpiPen 2pack Diphenhydramine 25mg tab #2 Sodium Chloride 0.9% 1000 mL Bag #1 Diphenhydramine 50mg/1mL vial #1
--	--

Nursing Orders for Home Infusion: MONITOR (IV only)
 Observe: Vital signs prior to infusion. Blood pressure and pulse every 15 minutes for first hour, then every 30 minutes until stable infusion rate, then every hour. Watch for: Signs of fluid overload, cardiovascular symptoms, allergic reactions, skin rash, fever, and moderate to severe headache.

PRN Orders:

Ondansetron 4mg slow IVP as premed for infusion induced nausea

Toradol 15mg-30mg SIVP as premed for infusion induced headache or muscle pain

Methylprednisolone 1 mg/kg (12.5 - 125 mg) slow IVP as pre-med or PRN for infusion-related cutaneous reaction or headache

Other: _____

PRESCRIBER INFORMATION

Physician name:		Practice site name:	
Address:		City:	State: Zip:
NPI:	Phone:	Fax:	

Office contact and special instructions:

*** Prescriber Authorization:** I authorize the pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Prescriber's signature: _____ **Date:** _____



Immune Globulin Pre-authorization Checklist

Help us speed authorization for treatment.

Please use this checklist to ensure all necessary documentation is submitted to support initial authorization of immune globulin (IG) therapy:

Autoimmune Disorders

- Completed referral form
- Insurance information (copy of insurance card/s preferred)
- Recent progress notes (two or more)
- Labs or diagnostic evidence supporting indication (e.g., electromyography, nerve conduction velocity, spinal tap or lumbar puncture, MRI, nerve and/or muscle biopsy, antibody testing)
- History of failure, contraindication or intolerance to other treatments (e.g., ace inhibitors, prednisone, azathioprine)

Primary Immunodeficiencies

- Completed referral form
- Insurance information (copy of insurance card/s preferred)
- Recent progress notes (two or more)
- History of failure with antibiotic treatment
- Pre-treatment IgG, IgA, IgM, and Ig subclass serum levels
- Current IgG, IgA, IgM, and IgG subclass serum levels
- Pre- and post-vaccine titers showing impaired antibody response to vaccine trial with pneumococcal, H influenza type B, or tetanus/diphtheria (measured 3-4 weeks after administration)